JPH04330014A - Gel ointment - Google Patents
Gel ointmentInfo
- Publication number
- JPH04330014A JPH04330014A JP5698591A JP5698591A JPH04330014A JP H04330014 A JPH04330014 A JP H04330014A JP 5698591 A JP5698591 A JP 5698591A JP 5698591 A JP5698591 A JP 5698591A JP H04330014 A JPH04330014 A JP H04330014A
- Authority
- JP
- Japan
- Prior art keywords
- indomethacin
- geraniol
- gel
- ointment
- gel ointment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【０００１】0001
【産業上の利用分野】本発明はインドメタシンの新規な
ゲル軟膏剤に関する。FIELD OF THE INVENTION This invention relates to a novel gel ointment of indomethacin.
【０００２】0002
【従来の技術及び発明が解決しようとする課題】インド
メタシンは非ステロイド系の優れた鎮痛消炎剤であるが
、水及び外用基剤として使用可能な各種溶剤にほとんど
溶けず、わずかにベンジルアルコール、テトラヒドロフ
ラン、ジメチルスルホキシド、ジメチルホルムアミド等
に溶解するが、これも量的、質的な点で外用製剤とする
には問題があるため、一般には経口剤の形で投与されて
きた。本発明者らは、インドメタシンの外用剤の研究に
おいて、先に、インドメタシンをアルコール−水系に含
有させてゲル軟膏とすることにより皮膚吸収の優れた外
用剤を得ることに成功し、特許出願した（特公昭５６−
１０８８６号）。そしてこのゲル軟膏は近年上市され、
臨床において高い評価を受けている。[Prior Art and Problems to be Solved by the Invention] Indomethacin is an excellent non-steroidal analgesic and anti-inflammatory agent, but it is hardly soluble in water and various solvents that can be used as external bases, and only slightly soluble in benzyl alcohol and tetrahydrofuran. , dimethyl sulfoxide, dimethyl formamide, etc., but these also have problems in terms of quantity and quality when used as external preparations, so they have generally been administered in the form of oral preparations. In our research into external preparations for indomethacin, we first succeeded in obtaining a topical preparation with excellent skin absorption by incorporating indomethacin into an alcohol-water system and making it into a gel ointment, and filed a patent application. Special Public Service 1977-
No. 10886). This gel ointment has been launched on the market in recent years.
It has received high praise in clinical practice.
【０００３】0003
【課題を解決するための手段】更に、本発明者らは、イ
ンドメタシンの溶剤に対する溶解性について研究を行っ
ていたところ、ある種のテルペノイド類又はフェノール
類がインドメタシンの各種溶剤への溶解性及び安定性を
増大することを見出し、本発明を完成した。[Means for Solving the Problems] Further, while conducting research on the solubility of indomethacin in solvents, the present inventors found that certain terpenoids or phenols improve the solubility and stability of indomethacin in various solvents. The present invention has been completed based on the discovery that the properties of the present invention can be increased.
【０００４】すなわち、本発明は、次の成分（Ａ）及び
（Ｂ）
（Ａ）インドメタシン
０．１〜５
重量％、（Ｂ）リモネン、ゲラニオール、カンフル及び
オイゲノールからなる群より選ばれる１種又は２種以上
の溶解補助剤
０．３〜１０重量％、を必須成分として含有するこ
とを特徴とするゲル軟膏剤を提供するものである。That is, the present invention provides the following components (A) and (B) (A) Indomethacin
0.1~5
% by weight, (B) one or more solubilizing agents selected from the group consisting of limonene, geraniol, camphor, and eugenol
The present invention provides a gel ointment characterized by containing 0.3 to 10% by weight as an essential component.
【０００５】本発明において、溶解補助剤は１種又は２
種以上を混合して使用することができ、その配合量はイ
ンドメタシンの量、溶剤の種類及び量によって異なるが
、一般に ０．３〜１０重量％の配合によって目的は達
成される。また、インドメタシンを溶解するための溶剤
としては、エタノール、プロパノール等のアルコール類
；アルコール−水混合系；ブチレングリコール、プロピ
レングリコール等のグリコール類；オリーブ油、大豆油
等の植物油；オレイン酸、リノール酸、リノレン酸等の
液状高級脂肪酸類；オクチルアルコール、ヘキサデシル
アルコール等の高級アルコール類；パラフィン、スクワ
ラン等の炭化水素類；Ｃ４ 〜Ｃ１４のモノカルボン酸
とＣ１ 〜Ｃ５ のアルコールとのエステル類、Ｃ４
〜Ｃ１０のジカルボン酸とＣ１ 〜Ｃ３ のアルコール
とのジエステル類等が挙げられる。本発明のゲル軟膏剤
は、インドメタシンを溶解補助剤、上記溶剤及び他のゲ
ル基剤に配合することにより製造される。この際のイン
ドメタシンの配合量は０．１〜５重量％が好ましい。[0005] In the present invention, one or two solubilizing agents are used.
A mixture of two or more species can be used, and the blending amount varies depending on the amount of indomethacin and the type and amount of the solvent, but the purpose is generally achieved by blending 0.3 to 10% by weight. In addition, solvents for dissolving indomethacin include alcohols such as ethanol and propanol; alcohol-water mixed systems; glycols such as butylene glycol and propylene glycol; vegetable oils such as olive oil and soybean oil; oleic acid, linoleic acid, Liquid higher fatty acids such as linolenic acid; Higher alcohols such as octyl alcohol and hexadecyl alcohol; Hydrocarbons such as paraffin and squalane; Esters of C4 to C14 monocarboxylic acids and C1 to C5 alcohols, C4
Diesters of ~C10 dicarboxylic acids and C1 ~C3 alcohols, etc. may be mentioned. The gel ointment of the present invention is produced by blending indomethacin with a solubilizing agent, the above-mentioned solvent, and another gel base. The amount of indomethacin blended at this time is preferably 0.1 to 5% by weight.
【０００６】[0006]
【発明の効果】叙上の如く、本発明の溶解補助剤を少量
添加するとインドメタシンの各種溶剤に対する溶解性及
び安定性が著しく増大するので、インドメタシンをゲル
基剤に高濃度で安定に配合したゲル軟膏剤を調製するこ
とができる。Effects of the Invention As mentioned above, the solubility and stability of indomethacin in various solvents are significantly increased by adding a small amount of the solubilizing agent of the present invention. Ointments can be prepared.
【０００７】[0007]
【実施例】次に実験例及び製剤例を挙げて説明する。
実験例１
インドメタシン溶解試験
各種溶媒に過剰量のインドメタシンを加え、更に表１に
示す量の溶解補助剤を加え、２５℃で２４時間振盪した
のち、遠心分離して上清を分取した。この上清中のイン
ドメタシン量をＵＶ法又はＨＰＬＣ法で測定し、溶解補
助剤無添加のものと比較した。その結果は表１のとおり
である。[Examples] Next, experimental examples and formulation examples will be given and explained. Experimental Example 1 Indomethacin dissolution test An excess amount of indomethacin was added to various solvents, and the amount of solubilizing agent shown in Table 1 was added, followed by shaking at 25° C. for 24 hours, followed by centrifugation to collect the supernatant. The amount of indomethacin in this supernatant was measured by a UV method or an HPLC method, and compared with that in which no solubilizing agent was added. The results are shown in Table 1.
【０００８】[0008]
【表１】[Table 1]
【０００９】製剤例１
インドメタシン
０．５（重量％）ゲラニオール
３．０プロピレングリ
コール １０．０カーボポ
ール９３４
１．０ジイソプロパノールアミン
１．０エタノール
４５．０精製水
全 １００．０Formulation Example 1 Indomethacin
0.5 (wt%) geraniol
3.0 Propylene Glycol 10.0 Carbopol 934
1.0 diisopropanolamine
1.0 ethanol
45.0 Purified water
Total 100.0
【００１
０】製剤例２001
0] Formulation example 2
Claims (1)
ドメタシン
０．１〜５重量％、（
Ｂ）リモネン、ゲラニオール、カンフル及びオイゲノー
ルからなる群より選ばれる１種又は２種以上の溶解補助
剤 ０．３
〜１０重量％、を必須成分として含有することを特徴と
するゲル軟膏剤。Claim 1: The following components (A) and (B) (A) indomethacin
0.1-5% by weight, (
B) One or more solubilizing agents selected from the group consisting of limonene, geraniol, camphor, and eugenol 0.3
A gel ointment characterized by containing ~10% by weight as an essential component.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5698591A JPH04330014A (en) | 1991-03-20 | 1991-03-20 | Gel ointment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5698591A JPH04330014A (en) | 1991-03-20 | 1991-03-20 | Gel ointment |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57072959A Division JPS58189115A (en) | 1982-04-30 | 1982-04-30 | Drug for external use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH04330014A true JPH04330014A (en) | 1992-11-18 |
| JPH0543683B2 JPH0543683B2 (en) | 1993-07-02 |
Family
ID=13042790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5698591A Granted JPH04330014A (en) | 1991-03-20 | 1991-03-20 | Gel ointment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH04330014A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100604244B1 (en) * | 2004-01-20 | 2006-07-25 | 나드리화장품주식회사 | Cosmetic composition containing tomato extract |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016018954B1 (en) * | 2014-03-24 | 2022-09-06 | Carl Zeiss Vision Inc. | METHOD AND SYSTEM FOR OPTIMIZING THE GEOMETRY OF AT LEAST ONE SEMI-FINISHED OPHTHALMIC LENS IN A SET OF SEMI-FINISHED OPHTHALMIC LENSES, COMPUTER PROGRAM CODE, TANGIBLE MEDIUM OF READY COMPUTER SUPPORT AND DATA SIGNAL |
-
1991
- 1991-03-20 JP JP5698591A patent/JPH04330014A/en active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100604244B1 (en) * | 2004-01-20 | 2006-07-25 | 나드리화장품주식회사 | Cosmetic composition containing tomato extract |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0543683B2 (en) | 1993-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS58189115A (en) | Drug for external use | |
| CA2231342C (en) | Pharmaceutical composition for oral delivery | |
| CA2784827A1 (en) | Composition of dexibuprofen transdermal hydrogel | |
| JP2002513750A (en) | Solvent / co-solvent free microemulsion and emulsion pre-concentrate drug delivery system | |
| JP2012505171A (en) | Sustained release emulsion for application to the skin or vaginal mucosa | |
| WO2011012816A2 (en) | Pharmaceutical formulation | |
| JPH08310964A (en) | Cyclosporin-containing soft capsule composition | |
| JPH026407A (en) | anti-inflammatory gel | |
| Ceschel et al. | In vitro permeation through porcine buccal mucosa of caffeic acid phenetyl ester (CAPE) from a topical mucoadhesive gel containing propolis | |
| JP2017503866A (en) | Composition for self-emulsifying drug delivery system comprising dutasteride | |
| CA2708203A1 (en) | Imiquimod formulation | |
| JPH107550A (en) | Soft capsule composition comprising cyclosporin | |
| JP3519414B2 (en) | Cycloporin-containing soft capsule formulation | |
| JPH07116026B2 (en) | External emulsion containing diclofenac sodium | |
| JPH0134968B2 (en) | ||
| US5463117A (en) | Process for the preparation of salts of 2-(4-isobutylphenyl)propionic acid | |
| EA033950B1 (en) | Transdermal formulation containing cox inhibitors | |
| JPH04330014A (en) | Gel ointment | |
| JP6480847B2 (en) | Loxoprofen-containing external preparation composition | |
| JPH0327533B2 (en) | ||
| JPS6399008A (en) | Transdermal composition | |
| JPH031289B2 (en) | ||
| JPS6218526B2 (en) | ||
| JPH0135807B2 (en) | ||
| JPS59137408A (en) | ointment |